Patients with chronic kidney disease (CKD) are often underrepresented in clinical trials evaluating the safety profile of newer medication classes for type 2 diabetes (T2D). Given the high burden of comorbidities and polypharmacy in this population, further safety research is needed. This study aimed to detect potential adverse events associated with sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with T2D and CKD, using a tree-based scan statistic approach.